If you have been reading about HGF mimetic and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
=== Economic reforms === The FSN had to choose between the two economic models that political elites claimed were available to post-Communist Eastern European countries: shock therapy or gradual reforms. The FSN chose the latter, slower reforms, because it would have not been possible to convince the people who were already "exhausted" after Ceaușescu's austerity to undergo further sacrifices. Nevertheless, neoliberal reforms were implemented, although not all at once: by the end of 1990, prices were liberalised and a free currency exchange rate was implemented, devaluing the leu by 60%. The land of the state-owned collective farms was distributed to private owners and a list of 708 large state-owned enterprises to be privatised was devised. In 1991 Romania signed an agreement with the IMF and began the privatisation of state-owned enterprises, with the first privatisation law being passed in 1991. In 1992, the Stolojan government began an austerity plan, limiting wages and further liberalising prices. The economic situation deteriorated and inflation as well as unemployment increased substantially. The austerity measures, which by 1995 included a decrease in social spending, led to an increase in poverty. The neoliberal reforms were accelerated after the Democratic Convention won the 1996 elections, the government using its prerogatives to pass a package of laws, removing subsidies, passing reforms on unemployment benefits and greatly increasing the number of privatised companies.
The Vanguard Group (8.97%) BlackRock (8.14%) State Street Corporation (4.26%) T. Rowe Price (3.92%) JPMorgan Chase (3.31%) Capital World Investors (2.93%) Fidelity Investments (2.49%) AllianceBernstein (2.23%) Geode Capital Management (2.11%) Pershing Square Capital Management (1.83%)
=== Non-amplifying === The initial mRNA vaccines use a non-amplifying mRNA construct. Non-amplifying mRNA has only one open reading frame that codes for the antigen of interest. The total amount of mRNA available to the cell is equal to the amount delivered by the vaccine. Dosage strength is limited by the amount of mRNA that can be delivered by the vaccine. Non-amplifying vaccines replace uridine with N1-Methylpseudouridine in an attempt to reduce toxicity.
=== Other concerns === A potentially significant problem following bisulfite treatment is incomplete desulfonation of pyrimidine residues due to inadequate alkalization of the solution. This may inhibit some DNA polymerases, rendering subsequent PCR difficult. However, this situation can be avoided by monitoring the pH of the solution to ensure that desulfonation will be complete. A final concern is that bisulfite treatment greatly reduces the level of complexity in the sample, which can be problematic if multiple PCR reactions are to be performed (2006). Primer design is more difficult, and inappropriate cross-hybridization is more frequent.
== Key Drivers of Drug Trafficking via the Southern Route == Drug trafficking activities in the WIO are influenced by a complex interplay of various factors. In addition to its strategic geographical location in close proximity to major drug-producing countries such as those of the Golden Crescent, and the limited law enforcement, political instability in many of the countries along the Southern Route may further exacerbate the problem. Illicit trade, such as drug trafficking, is often found in fragile states as an additional or alternative source of income. The political instability in Pakistan and Afghanistan, especially after the withdrawal of the US Troops from Afghanistan is likely to have influenced the increasing poppy yield in Afghanistan requiring shipping. According to the Fragile State Index (2023), the vast majority of states in the WIO are ranked under the ‘warning’ or ‘alert’ categories, including Afghanistan, which is ranked 106.6 out of the maximum 120. Globalisation may also have influenced trafficking routes, as global licit trade has increased, with about half of the worlds container traffic passing through the WIO, which presents ample opportunities for traffickers to take advantage of the existing shipping infrastructure.
Sources: en.wikipedia.org
H2O2 + R'H2 → R' + 2 H2O thus eliminating the poisonous hydrogen peroxide in the process. This reaction is important in liver and kidney cells, where the peroxisomes neutralize various toxic substances that enter the blood. Some of the ethanol humans drink is oxidized to acetaldehyde in this way. In addition, when excess H2O2 accumulates in the cell, catalase converts it to H2O through this reaction:
== History == References to dedifferentiation can be found as far back as 1915, where Charles Manning Child described dedifferentiation as a “return or approach to the embryonic or undifferentiated condition”. While Manning's research was about plants, it helped establish the foundation for our modern-day understanding of dedifferentiation and cell plasticity. Just as plant cells respond to injury by undergoing callus formation via dedifferentiation, some animal models dedifferentiate their cells to form blastema, which are analogous to plant calluses, after limb amputation. In the 1940s C. H. Waddington created the “Epigenetic Landscape”, a diagrammatic representation of cell fate from less differentiated to more differentiated cell types. Here, the concept of a marble moving downhill through various paths is used to represent cell decision-making and cell potency, thus visualizing how cells can take different paths of differentiation to reach a final state. Dedifferentiation would be represented by the marble moving uphill through the pathways it has already taken until it settles somewhere above the most downhill location. In our modern-day understanding of dedifferentiation, some controversies remain when defining the boundaries of its definition. Some claim that dedifferentiation is strictly limited to the same cell lineage from which it is derived. However, others say that it can be used to describe a general increase in cell potency.
== History == Composition is widely accepted to have been developed by Thomas Jackson in London around the late 18th century. His son, George Jackson, continued the business. His company, George Jackson, still trades today and supplies composition ornament made to the original methods and recipe.
== Detection == Alan Fryday (1991) outlined a technique for the detection of confluentic acid in lichen samples. This method involves placing a section of the lichen's thallus or apothecium (fruiting body) on a microscope slide, which is then saturated with a 10% potassium hydroxide (KOH) solution. When examined under a compound microscope at 40x magnification, a distinctive 'halo' of small oil droplets or bubbles emanating from the tissue section indicates the presence of confluentic acid. The oil droplets generated during this detection process consist of 4-O-methylolivetonide, a compound that is insoluble in potassium hydroxide solution. This substance forms as a result of confluentic acid undergoing hydrolysis in the presence of potassium hydroxide. This test is useful in distinguishing between morphologically similar yet chemically distinct species within the genus Porpidia.
Sources: en.wikipedia.org
== Bibliography == Agoncillo, Teodoro C. (1990) [1960]. History of the Filipino People (8th ed.). Quezon City: Garotech Publishing. ISBN 971-8711-06-6. Bautista, Alberto Manuel (1952). The Hukbalahap Movement in the Philippines, 1942-1952. University of California. Greenberg, Lawrence M. (1987). "V. Ramon Magsaysay, Edwards Landsdale, and the Jusmag". The Hukbalahap Insurrection: A Case Study of a Successful Anti-Insurgency Operation in the Philippines, 1946–1955. United States Army Center of Military History. Library of Congress Catalog Card Number: 86-600597. Archived from the original on May 21, 2011. Retrieved August 12, 2008. Greenberg, Lawrence M. (1987). "VI. The Insurrection – Phase II (1950–1955)". The Hukbalahap Insurrection: A Case Study of a Successful Anti-Insurgency Operation in the Philippines, 1946–1955. United States Army Center of Military History. Library of Congress Catalog Card Number: 86-600597. Archived from the original on May 21, 2011. Retrieved August 12, 2008. Martinez, Manuel F. (2002). "Mission Possible: Assassinate Quezon – and Mrs. Quezon". Assassinations and Conspiracies: From Rajah Humabon to Imelda Marcos. Pasig: Anvil Publishing, Inc. pp. 138–152. ISBN 971-27-1218-4. McClintock, Michael (1992). "4. Toward a New Counterinsurgency: Philippines, Laos, Vietnam". Instruments of Statecraft: U.S. Guerella Warfare, Counterinsurgency, and Counterterrorism, 1940-1990. Pantheon Books. Valeriano, Napoleon D. "Military Operations". Counter-Guerrilla Seminar Fort Bragg, 15 June 1961.
The head (Latin: caput). The head of the epididymis receives spermatozoa via the efferent ducts of the mediastinum of the testis at the superior pole of the testis. The head is characterized histologically by a thick epithelium with long stereocilia (described below) and a little smooth muscle. It is involved in absorbing fluid to make the sperm more concentrated. The concentration of the sperm here is dilute. The body (Latin: corpus). This has an intermediate epithelium and smooth muscle thickness. The tail (Latin: cauda). This has the thinnest epithelium of the three regions and the greatest quantity of smooth muscle. The tail is distally continuous with (the convoluted portion of) the ductus deferens (s. vas deferens).
Noradrenergic and serotonergic nuclei in the ARAS are involved in the regulation of the REM sleep cycle and function as "REM-off" cells, with amphetamine's effect on norepinephrine and serotonin contributing to the suppression of REM sleep and a possible reduction of cataplexy at high doses. The American Academy of Sleep Medicine (AASM) 2021 clinical practice guideline conditionally recommends dextroamphetamine for the treatment of both type 1 and type 2 narcolepsy. Treatment with pharmaceutical amphetamines is generally less preferred relative to other stimulants (e.g., modafinil) and is considered a third-line treatment option. Medical reviews indicate that amphetamine is safe and effective for the treatment of narcolepsy. Amphetamine appears to be most effective at improving symptoms associated with hypersomnolence, with three reviews finding clinically significant reductions in daytime sleepiness in patients with narcolepsy. Additionally, these reviews suggest that amphetamine may dose-dependently improve cataplexy symptoms. However, the quality of evidence for these findings is low and is consequently reflected in the AASM's conditional recommendation for dextroamphetamine as a treatment option for narcolepsy.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.